ArticleMammalian genome : official journal of the International Mammalian Genome Society2021
CircRNA circ-ATAD1 is downregulated in endometrial cancer and suppresses cell invasion and migration by downregulating miR-10a through methylation.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- circ-ATAD1 as Competing Endogenous RNA for miR-191-5p Forces Non-small Cell Lung Cancer Progression.Applied biochemistry and biotechnology · 2024Article
- Circular RNA circ_0101675 Promotes NSCLC Cell Proliferation, Migration, Invasion, Angiogenesis and Immune Evasion by Sponging miR-607/PDL1 Axis.Biochemical genetics · 2024Article
- Genetic Deletion of Thorase Causes Purkinje Cell Loss and Impaired Motor Coordination Behavior.Cells · 2023Article
- Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review).Oncology letters · 2023Review
- Circular RNAs in endometrial carcinoma (Review).Oncology reports · 2022Review
- Interactions of circRNAs with methylation: An important aspect of circRNA biogenesis and function (Review).Molecular medicine reports · 2022Article
- Recent Updates on the Role of the MicroRNA-10 Family in Gynecological Malignancies.Journal of oncology · 2022Review
- Insights into the role of long non-coding RNAs in DNA methylation mediated transcriptional regulation.Frontiers in molecular biosciences · 2022Review
Corrections and comments
- Retraction · 2023-06-19Lack of IRB/IACUC Approval and/or Compliance ·
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that circ-ATAD1 promotes the development of gastric cancer. This study was carried out to analyze the role of circ-ATAD1 in endometrial cancer (EC). EC and paired non-tumor tissues from EC patients (n = 60) were subjected to the isolation of total RNA and RT-qPCR to analyze the expression of circ-ATAD1 and miR-10a. Correlations between circ-ATAD1 and miR-10a were analyzed by Pearson's correlation coefficient. The effects of circ-ATAD1 overexpression on miR-10a expression and methylation were analyzed by RT-qPCR and methylation-specific PCR (MSP). The roles of circ-ATAD1 and miR-10a in regulating EC cell invasion and migration were analyzed by Transwell assays. We found that circ-ATAD1 was downregulated in EC, while miR-10a was upregulated in EC. An inverse correlation between circ-ATAD1 and miR-10a was observed across EC samples. In EC cells, circ-ATAD1 overexpression decreased miR-10a expression and increased miR-10a gene methylation. Transwell assay analysis showed that circ-ATAD1 overexpression totally reversed the enhancing effects of miR-10a on EC cell invasion and migration. Circ-ATAD1 is downregulated in EC and may suppress EC cell invasion and migration by downregulating miR-10a through methylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.